['\xe2\x86\x91 INDICATES INCREASE. \xe2\x86\x93 INDICATES DECREASE. A ONLY IF OTHER DRUGS ARE NOT AVAILABLE AND IF CLEARLY INDICATED. IF TREATMENT WITH LIFE-SUSTAINING DRUGS THAT CAUSE PANCREATIC TOXICITY IS REQUIRED, SUSPENSION OF DIDANOSINE IS RECOMMENDED [SEE WARNINGS AND PRECAUTIONS (5.1) ] . B [SEE WARNINGS AND PRECAUTIONS (5.6) .]', 'DRUGS THAT MAY CAUSE PANCREATIC TOXICITY', '\xe2\x86\x91 RISK OF PANCREATITIS', 'USE ONLY WITH EXTREME CAUTION A', 'NEUROTOXIC DRUGS', '\xe2\x86\x91 RISK OF NEUROPATHY', 'USE WITH CAUTION B', 'ANTACIDS CONTAINING MAGNESIUM OR ALUMINUM', '\xe2\x86\x91 SIDE EFFECTS ASSOCIATED WITH ANTACID COMPONENTS', 'USE CAUTION WITH DIDANOSINE TABLETS FOR ORAL SUSPENSION AND DIDANOSINE PEDIATRIC POWDER FOR ORAL SOLUTION', 'AZOLE ANTIFUNGALS', '\xe2\x86\x93 KETOCONAZOLE OR ITRACONAZOLE CONCENTRATION', 'ADMINISTER DRUGS SUCH AS KETOCONAZOLE OR ITRACONAZOLE AT LEAST 2 HOURS BEFORE DIDANOSINE.', 'QUINOLONE ANTIBIOTICS (SEE ALSO CIPROFLOXACIN IN TABLE 9)', '\xe2\x86\x93 QUINOLONE CONCENTRATION', 'CONSULT PACKAGE INSERT OF THE QUINOLONE.', 'TETRACYCLINE ANTIBIOTICS', '\xe2\x86\x93 ANTIBIOTIC CONCENTRATION', 'CONSULT PACKAGE INSERT OF THE TETRACYCLINE.']DIDANOSINE DELAYED-RELEASE CAPSULES. PATIENTS SHOULD BE CLOSELY MONITORED FOR ADEQUATE CLINICAL RESPONSE WHEN DIDANOSINE DELAYED-RELEASE CAPSULES ARE COADMINISTERED WITH METHADONE, INCLUDING MONITORING FOR CHANGES IN HIV RNA VIRAL LOAD.', 'NELFINAVIR', '\xe2\x86\x93 NO INTERACION 1 HOUR AFTER DIDANOSINE', 'ADMINISTER NELFINAVIR 1 HOUR AFTER DIDANOSINE.', 'TENOFOVIR DISOPROXIL FUMARATE', '\xe2\x86\x93 DIDANOSINE CONCENTRATION', 'A DOSE REDUCTION OF DIDANOSINE TO THE FOLLOWING DOSAGE ONCE DAILY IS RECOMMENDED. A 250 MG (ADULTS WEIGHING AT LEAST 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60 ML/MIN) 200 MG (ADULTS WEIGHING LESS THAN 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60 ML/MIN) DIDANOSINE AND TENOFOVIR DISOPROXIL FUMARATE MAY BE TAKEN TOGETHER IN THE FASTED STATE. IF TENOFOVIR DISOPROXIL FUMARATE IS TAKEN WITH FOOD, DIDANOSINE SHOULD BE TAKEN ON AN EMPTY STOMACH (AT LEAST 30 MINUTES BEFORE FOOD OR 2 HOURS AFTER FOOD). PATIENTS SHOULD BE MONITORED FOR DIDANOSINE\xc2\xad-ASSOCIATED TOXICITIES AND CLINICAL RESPONSE.']